Pacgen Enters Into Exclusive Distribution Agreement With Arise Biotech Corporation

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 10, 2012) - Pacgen Life Science Corporation ("Pacgen" or the "Company") (PBS.V) announced today that Pacgen Inc., the Company's wholly owned subsidiary based in Irvine, California USA, has signed an exclusive distribution agreement with Arise Biotech Corporation ("Arise") to distribute Arise's automated pipetting systems and electronic pipettes in the United States.

"We have selected Arise's automated micro-liquid handling technologies and digital pipettes products for distribution in the US market and have already installed their systems in our customer laboratories," said Dr. Ming S. Liu, Chief Executive Officer of Pacgen. "Pacgen has undertaken a number of business initiatives and plans to continue strengthening its bio-products portfolio for distribution," added Dr. Liu.

About Pacgen
Pacgen is a life science technology company focused on the commercialization of biomedical products and services, including its previous development of novel therapeutic drug candidates. The Company is currently looking to facilitate its corporate transformation from a bio-pharma R&D business into a revenue-generating company. For additional information, please visit

About Arise Biotech Corporation
Arise Biotech Corporation is a customer-oriented, innovative company established in Taipei, Taiwan in 2002. Arise designs, manufactures, and markets liquid handling products, such as electronic pipettes, electronic pipette aids and tips, etc. under its own brand name and OEM/ODM partners' brand names. Our goal is to bring comfort, accuracy and convenience to our customers, so they can efficiently conduct their experiments and enjoy their research process at the same time. For additional information, please visit

Forward looking Statements
Certain statements included in this press release may be considered forward-looking. Statements relating to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments constitute forward-looking statements. All forward-looking statements are based on Pacgen's current beliefs and expectations as well as assumptions relating to the successful completion of its clinical trials and pre-clinical studies, the time and process required to obtain regulatory approval for commercialization of its product, the ability of Pacgen to raise additional capital in future on favourable terms, the impact of competitive products and pricing in the market, new product development, and the successful and timely completion of corporate collaborations or licensing arrangements for its research programs. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with completion of clinical trials and obtaining regulatory approval, dependence on collaborative partners, and our ability to protect our intellectual property.

Wherever possible, words such as "anticipate", "believe", "expect", "may", "could", "will", "potential", "intend", "estimate", "should", "plan", "predict", "project" or the negative or other variations of such expressions reflect Pacgen's current beliefs and assumptions and are based on the information currently available to Pacgen. Certain risks and uncertainties, including those risk factors identified by Pacgen in its annual management's discussion and analysis dated July 29, 2011 and annual information form dated July 31, 2008, may cause our actual results, level of activity, performance or achievements to differ materially from those implied by forward looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Pacgen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For all forward-looking statements, Pacgen claims the safe harbour for forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Ming S. Liu
Pacgen Life Science Corporation
Chief Executive Officer